The Challenge
This Series B oncology biotech was preparing to launch a critical Phase II trial across 8 clinical sites. Like many small biopharmas, they had assembled their technology stack piece by piece: one vendor for their eISF, another for EDC, a third for eTMF, and a fourth for site communication.
The result was a fragmented, expensive mess. The team was burning $50,000 per month just on vendor management, integration maintenance, and data reconciliation between systems. Every time a site coordinator entered data, it had to be verified across multiple platforms.
Worse yet, the study startup process had stretched to 6 months. Each vendor required separate validation, separate training for site staff, and separate contracts. The company's funding runway was shrinking while their trial timeline kept extending.
Clincove gave us the infrastructure of a top-10 pharma company at a fraction of the cost. We went from vendor chaos to a single source of truth in weeks.
VP of Clinical Operations
The Solution
The biotech deployed Clincove's unified platform in just 3 weeks. By consolidating their eISF, EDC, eTMF, and site communication into a single system, they eliminated the integration burden entirely.
Four separate vendor contracts became one. Four separate logins for site staff became one. Four separate validation processes became one. The simplification was immediate and dramatic.
Clincove's guided setup wizard and built-in compliance templates meant the team didn't need months of configuration. The platform was ready for 21 CFR Part 11 compliant data collection from day one, with audit trails and electronic signatures built in.
The Results
The most dramatic improvement was in study startup time. What previously took 6 months of vendor coordination, validation, and training was compressed to just 6 weeks with Clincove. Sites were onboarded in days instead of weeks, and data began flowing immediately.
The 60% cost reduction in vendor spend freed up critical budget for patient recruitment. And with 90% fewer data queries, the clinical operations team could focus on science instead of troubleshooting data discrepancies between systems.
What's Next
Buoyed by the success of their Phase II trial, the biotech is now planning a pivotal Phase III study across 24 sites using Clincove as their sole operational platform. They're also leveraging Clincove's Protocol AI to auto-generate CRFs and visit schedules from their protocol, expecting to further compress study startup time.